Changes in body composition in patients with left ventricular systolic dysfunction initiated on beta-blocker therapy by Ingle, Lee et al.
  
 
© 2007, Pulsus Group Inc. All rights reserved. This is an Open Access 
article, distributed under the terms of the Creative Commons 
Attribution license. 
Ingle, L, Rigby, AS, Carroll, S, Butterly, R, King, RF, Cooke, CB, Cleland, 
JGJF & Clark, AL 2007, 'Changes in body composition in patients with 
left ventricular systolic dysfunction initiated on beta-blocker therapy' 
Experimental and Clinical Cardiology, vol 12, no. 1, pp. 46-47. 
Exp Clin Cardiol Vol 12 No 1 200746
Changes in body composition in patients with 
left ventricular systolic dysfunction initiated on 
beta-blocker therapy
Lee Ingle PhD1, Alan S Rigby PhD2, Sean Carroll PhD1, Ron Butterly PhD1, Rod F King PhD1, 
Carlton B Cooke PhD1, John GJF Cleland MD2, Andrew L Clark MD2
1Carnegie Research Institute, Leeds Metropolitan University, Beckett’s Park Campus, Leeds; 2Department of Academic Cardiology, 
University of Hull, Castle Hill Hospital, Cottingham, United Kingdom
Correspondence: Dr Andrew L Clark, Department of Academic Cardiology, University of Hull, Castle Hill Hospital, Cottingham, 
Kingston-upon-Hull HU16 5JQ, United Kingdom. Telephone 01-482-624012, fax 01-482-624071, e-mail A.Clark@hull.ac.uk
Received for publication April 6, 2006. Accepted September 5, 2006
L Ingle, AS Rigby, S Carroll, et al. Changes in body
composition in patients with left ventricular systolic
dysfunction initiated on beta-blocker therapy. Exp Clin Cardiol
2007;12(1):46-47.
BACKGROUND: Increasing body mass index, cholesterol and
body fat are associated with a better prognosis in patients with left
ventricular systolic dysfunction (LVSD). Beta-blocker usage is associ-
ated with changes in body composition and increased body fat. The
present study investigated 12-month changes in body composition in
patients with LVSD initiated on beta-blocker therapy.
METHODS: The relation between beta-blocker use and body
composition was evaluated in 91 patients (75% male) with LVSD.
Body composition was assessed by bioelectrical impedance.
RESULTS: Seventeen patients died during the study period. There
was no statistical difference among beta-blocker usage, beta-blocker
type, or changes in body fat, basal metabolic rate, impedance, fat-free
mass, fat mass and total body water. There were no significant differ-
ences between any of these measures and beta-blocker usage. 
CONCLUSION: After 12 months, changes in body composition
were not found to be influenced by initiation of beta-blocker therapy
in patients with LVSD.
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Chronic heart failure (CHF) is a prevalent and deadly con-dition (1). Patients with CHF have an increased resting
metabolic rate, which may be related to the development of
cardiac cachexia (2). Patients with cachexia have a worse
prognosis than patients without cachexia but both experience
a similar degree of left ventricular systolic dysfunction (LVSD)
(3,4). Conversely, while thinner patients have a poorer progno-
sis, increasing body mass index (BMI) (4,5) and body fat (6)
are associated with a better outcome.
Beta-blocker therapy is undoubtedly beneficial to patients
with CHF, irrespective of symptom severity (7). Previous work
has shown that long-term beta-blocker use is associated with
increased weight gain compared with placebo-controlled
patients following acute myocardial infarction (8). A recent
pilot study (9) claimed that beta-blockers may increase body fat
mass and total body fat in patients with CHF, and short-term
beta-blocker use was associated with reversal of muscle protein
catabolism in children suffering from severe burns (10). We
aimed to investigate 12-month changes in body composition in
patients with CHF initiated on beta-blocker therapy.
METHODS
The Hull and East Riding Ethics Committee approved the study, and
all patients provided informed consent for participation. Body com-
position was determined by bioelectrical impedance assessment
(Tanita TBF 410-MA, Tanita Corp, Japan). Patients would step onto
the bioelectrical impedance analysis scales, and a safe electrical sig-
nal was conducted across the shortest distance between two fixed
points (each foot) to measure impedance. The premise of this appli-
cation is that while body fat resists the electrical signal (impedance),
lean tissue (containing more water) allows the signal to pass more
easily. Fifty-two per cent of patients were initiated on carvedilol,
36% bisoprolol, 8% atenolol and 4% others.
CHF was defined in accordance with the European Society of
Cardiology (11). Left ventricular function was determined from
two-dimensional echocardiography and was carried out by one of
three trained operators. Left ventricular ejection fraction (LVEF)
was calculated using the Simpson’s formula from measurements of
end-diastolic and end-systolic volumes on apical two-dimensional
views, and LVSD was diagnosed if LVEF was 45% or less. 
The relation between changes in body fat, body mass, fat mass
or fat-free mass, and beta-blocker usage was investigated by least
squares regression analysis, taking beta-blocker as a factor at two
levels (any versus none) and beta-blocker type (none, atenolol,
bisoprolol, carvedilol and any other). The appropriateness of the
least squares model was examined by plotting residuals. The resid-
ual plots showed no obvious departure from normality. All regres-
sion analyses were corrected for age, sex and baseline BMI. Paired
samples t tests were used to identify differences between baseline
and follow-up in surviving patients. An arbitrary level of 5% sta-
tistical significance (two-tailed) was assumed.
RESULTS
A total of 91 consecutive unselected patients (75% male) diag-
nosed with LVSD (mean age 72±11 years; BMI 28.0±5.3 kg/m2;
body mass 80.6±15.0 kg; mean LVEF 32±9%) and body fat
(30.9±14.0%), fat mass (24.7±12.3 kg) and fat-free mass
(56.6±10.2 kg) were studied .
Of the initial 91 patients, 17 died (19%) before follow-up.
The mean follow-up period was 12±2 months. After 12 months,
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mean BMI was 28.4±5.5 kg/m2, P>0.05; body mass was
81.2±17.0 kg, P>0.05; body fat was 31.3±14.2%, P>0.05; fat
mass was 25.3±13.2 kg, P>0.05; and fat-free mass was
56.3±10.0 kg, P>0.05 (Table 1). Therefore, mean body fat
increased by 0.4±0.12 kg, fat mass increased by 0.6±0.20 kg,
body mass increased by 0.6±0.17 kg and fat-free mass decreased
by 0.3±0.06 kg after 12 months. 
There was no statistical difference among beta-blocker
usage, beta-blocker type, or changes in body fat, basal meta-
bolic rate, impedance, fat-free mass, fat mass and total body
water. There was also no difference between beta-blocker
usage, beta-blocker type and body composition. 
DISCUSSION
In the cohort of patients with LVSD, body mass, fat mass and
body fat increased after 12 months, but not significantly. No dif-
ferences existed between beta-blocker usage or beta-blocker type
and changes in body composition. Therefore, after 12 months,
changes in body composition were not influenced by initiation
of beta-blocker therapy in patients with LVSD.
There are a dearth of studies that have examined temporal
changes in body composition in patients with CHF. In a study by
Rossner et al (9), 3837 men and women were randomly assigned
to receive propranolol or placebo, five to 21 days after acute
myocardial infarction, for up to 40 months. A mean weight gain
of 1.2 kg (95% CI 0.9 kg to 1.5 kg) was reported. Recently, a
study by Lainscak et al (8) reported that treatment with beta-
blockers may increase fat mass and body fat in patients with CHF.
However, this study included only 41 patients, and the statistical
analysis was limited. It was postulated that drug-dependent
mechanisms for weight gain included a reduced basal metabolic
rate, a reduced thermogenic response and inhibition of lipolysis,
which have been reported in other studies (12-15).
To determine if body composition is affected by beta block-
ade in patients with CHF, it is important to individually deter-
mine how long each patient had been prescribed the
medication. In our patients, the duration of therapy was not a
predictor of changes in body composition. It may have been
that the influence of beta blockade on body composition takes
longer than 12 months to manifest in CHF. Therefore, further
long-term studies (in excess of 12 months) are required. Future
investigations should also examine whether temporal changes
in body composition affect survival rates in patients with CHF.
In conclusion, after 12 months, changes in body composition
were not found to be influenced by initiation of beta-blocker
therapy in patients with LVSD.
TABLE 1
Clinical characteristics of patients at baseline and 
12 months later
Variable Baseline 12 months P
n 91 91 –
Males (%) 75 75 –
Age (years) 72.0±11.1* 73.0±11.1* –
Body mass index (kg/m2) 28.0±5.0* 28.4±5.5* 0.27
LVEF (%) 32±9* 39±12*† 0.01
Body fat (%) 30.9±14.0* 31.3±14.2* 0.44
Fat mass (kg) 24.7±12.3* 25.3±13.2* 0.35
Body mass (kg) 80.6±15.0* 81.2±17.0* 0.28
Fat-free mass (kg) 56.6±10.2* 56.3±10.0* 0.52
Basal metabolic rate (kJ) 466±249* 448±134* 0.49
Total body water (%) 41.2±8.1* 42.0±8.3* 0.25
Impedance (ohms) 6349±1304* 6382±1407* 0.46
Diuretics (%) 62 75† 0.01
ACE inhibitor (%) 51 75† 0.001
Atrial fibrillation (%) 26 22 0.35
Smoking status (%) 8 9 0.69
Renal impairment (%) 26 23 0.55
*Values are mean ± SD; †Significant difference (P<0.05). ACE Angiotensin-
converting enzyme; LVEF Left ventricular ejection fraction
TABLE 2
Relationship between beta-blocker usage and per cent
changes in body fat after 12 months in patients with left
ventricular systolic dysfunction
Variable Level Mean difference (95% CI) P
Beta-blocker None 11.9 (10.8,13.3)
Any 11.7 (10.7,12.7) 0.61
Type Atenolol 12.1 (9.9,14.2)
Bisoprolol 12.7 (10.9,14.4)
Carvedilol 10.8 (9.4,12.3)
Other 11.7 (8.5,14.9) 0.79
Mean values are adjusted for age, sex and body mass index. Other beta-
blockers were celiprolol, metoprolol, propranolol, sotalol and timolol
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